The pharmaceutical company Janssen, belonging to the American multinational Johnson & Johnson, plans to have the vaccine against covid-19, in whose phase III trials Spain participates, in the second half of 2021 to a price less than 10 dollars.
This was revealed this Thursday by the Vice President of the Executive Committee of Johnson & Johnson, Joaquín Duato, at a conference at the Sectorial Meeting of the Health Sector, organized by IESE Business School, with the collaboration of the consulting firm McKinsey & Company.
Duato took advantage of the event to announce the incorporation of 60,000 new volunteers to the Janssen clinical trial, 30,000 more than required in a first appeal.
The study, approved yesterday in Spain by the Spanish Agency for Medicines and Health Products, plans to guarantee the vaccine “sometime in the first or second half of 2021”, has declared.
The first clinical results from Pfizer and Moderna, with 95% efficiency, are figures that suppose “good omens” for the rest of the pharmaceutical companies focused on the same protein.
As reported by the Johnson & Johnson executive, the pharmaceutical company has worked in the supply chain to be able to offer billion vaccines in 2021 through a collaborative network.
“During the next six months there will be good newsWe will be able to see how these effective vaccines will be available to the public, “stressed Duato, who took the opportunity to emphasize that the vaccine his team works on will also guarantee” the quality and safety standards “announced by other companies in the sector.
The speaker applauded the collaboration between partners in the pharmaceutical industry to find a vaccine: “It is not a competitive situation, it is a social issue and a global crisis in which we will need several vaccines, not just one, because we must vaccinate millions of people. ”
To guarantee the vaccination of the population, Johnson & Johnson works together with governments on access and distribution plans, such as COVAX, a project to which 500 million doses will be allocated of its production for the lower-income countries.
“We must create international supply chains, it doesn’t help us to focus on a single country “, Duato pointed out.
From the multinational they assure that the price will not focus on profit: “We will seek to guarantee access to the vaccine in all territories, the price will not be more than 10 dollars per vaccine. ”
Spain is one of the participants in the Janssen study, currently in phase III, which will take place at the University of Navarra Clinic, La Paz University Hospital, Quirón Salud Madrid University Hospital, La Princesa University Hospital, Quirón Salud Barcelona Hospital, Vall d’Hebron University Hospital, Hospital Clínic de Barcelona and the Germans Trias i Pujol Hospital in Badalona.